Free Trial

OmniAb Q2 2023 Earnings Report

OmniAb logo
$3.50 0.00 (0.00%)
(As of 12/20/2024 05:16 PM ET)

OmniAb EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.11
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

OmniAb Revenue Results

Actual Revenue
$6.95 million
Expected Revenue
$13.05 million
Beat/Miss
Missed by -$6.10 million
YoY Revenue Growth
N/A

OmniAb Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

OmniAb Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Stifel Nicolaus Keeps Their Buy Rating on OmniAb (OABI)
See More OmniAb Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OmniAb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OmniAb and other key companies, straight to your email.

About OmniAb

OmniAb (NASDAQ:OABI), a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

View OmniAb Profile

More Earnings Resources from MarketBeat

Upcoming Earnings